A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

NCT07790861 · Not yet recruiting

Last updated 2026-08-28

This clinical trial is testing the medication Orforglipron (LY3502970) in Chinese adults who have obesity or are overweight and related health issues to see how it affects their body weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 192 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-12 · est. completion 2028-03

Where 13 sites · China

What this study is testing ClinicalTrials.gov NCT07790861 ↗

Description as written by the study sponsor.

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Mean Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07790861 ↗